Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA)

BioIPSeeds Trusted Platform

BioIPSeeds creates a new model for academia-industry interaction by providing an effective, safe and trustful environment.

TRPMA Conference Services

Our bright and elegant conference room is the best place for company events with a spacious lobby for socializing and freshly prepared refreshments directly from the Southern Harbor Cafe...

Rising Star
Taiwan New Drug

Click here for more details about the global planning of Taiwan new drug R&S and clinical trials

BioPharmaceutical Analyst Program

Taiwan: TRPMA and DTCO Jointly Announce the Development of “TRPMA Biopharma Trusted Platform”

Taiwan: TRPMA and DTCO Jointly Announce the Development of “TRPMA Biopharma Trusted Platform”

(Source: TRPMA 2016-05-10）

Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA) announced the collaboration with Digital Treasury Corporation (DTCO) to jointly develop the “TRPMA Biopharma Trusted Platform”, an application of the latest Blockchain Technology.

Read More

Welcome to TRPMA website

Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA), composed of 28 Taiwanese innovative biopharmaceutical companies, plays a pivotal role in coordinating the resources, strengthening alliances among the industry, the academic and the government in Taiwan. TRPMA members aim to create a competitive value chain of biopharmaceutical industry to boost the nation's economy and promote the Asian and global cooperation in biopharmaceutical innovation.

Industry News

US: FDA finalizes guidance on microdose radiopharmaceutical diagnostic drugs

The US Food and Drug Administration (FDA) on Monday finalized guidance to help sponsors of microdose radiopharmaceutical diagnostic drugs on the nonclinical studies recommended to support human clinical trials and marketing applications.

Read More
UK: Why companies should bring biosimilar studies to the UK

With the patent protection for a number of leading biologic drugs set to expire in the coming years, the race is on within the life sciences industry to develop lower cost alternatives, known as biosimilars. Biologic medicines have revolutionised the treatment of many serious and chronic illnesses in the NHS, ranging from cancer through to rheumatoid arthritis and inflammatory bowel disease. Yet they are costly to develop and manufacture, which means they are expensive for the NHS to prescribe to patients.

Read More
EU: EMA proposes reducing data requirements for rG-CSF biosimilars

EMA is planning to reduce the data requirements for developers of recombinant granulocyte colony stimulating factor (rG-CSF) biosimilars. The proposed changes echo broader shifts in EMA’s approach to biosimilars by reducing the need to run animal tests and clinical trials.

Read More